Earlier this week, SymbioCellTech received confirmation that a Pre-IND Meeting has been granted with the Center for Biologics Evaluation and Research (CBER) at the FDA to discuss plans to move into human clinical trials with Neo-Islet therapy. “This represents another favorable step toward realizing a better therapy and potential cure for millions of people suffering from insulin-dependent diabetes,” states Christof Westenfelder, MD, Chief Executive Officer of SymbioCellTech, LLC.